313 related articles for article (PubMed ID: 32060929)
1. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR; Rybak JM; Claeys KC
Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929
[TBL] [Abstract][Full Text] [Related]
2. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.
Heo YA
Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination.
Mansour H; Ouweini AEL; Chahine EB; Karaoui LR
Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections.
Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127
[TBL] [Abstract][Full Text] [Related]
5. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
7. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C; Vasile L; Sandesc D; Venskutonis D; McLeroth P; Lala M; Rizk ML; Brown ML; Losada MC; Pedley A; Kartsonis NA; Paschke A
Antimicrob Agents Chemother; 2016 Oct; 60(10):6234-43. PubMed ID: 27503659
[TBL] [Abstract][Full Text] [Related]
8. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217
[TBL] [Abstract][Full Text] [Related]
10. New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
O'Donnell JN; Lodise TP
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0025622. PubMed ID: 35727059
[TBL] [Abstract][Full Text] [Related]
11.
Powles MA; Galgoci A; Misura A; Colwell L; Dingley KH; Tang W; Wu J; Blizzard T; Motyl M; Young K
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866878
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
14. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.
Young K; Painter RE; Raghoobar SL; Hairston NN; Racine F; Wisniewski D; Balibar CJ; Villafania A; Zhang R; Sahm DF; Blizzard T; Murgolo N; Hammond ML; Motyl MR
BMC Microbiol; 2019 Jul; 19(1):150. PubMed ID: 31272373
[TBL] [Abstract][Full Text] [Related]
15. New evidence in severe pneumonia: imipenem/ cilastatin/relebactam.
Girón RM; Ibáñez A; Gómez-Punter RM; Alarcón T
Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):46-49. PubMed ID: 35488826
[TBL] [Abstract][Full Text] [Related]
16. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
17. Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.
Lob SH; Hoban DJ; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2018 Dec; 15():12-19. PubMed ID: 29857057
[TBL] [Abstract][Full Text] [Related]
18.
Lob SH; Karlowsky JA; Young K; Motyl MR; Hawser S; Kothari ND; Sahm DF
J Med Microbiol; 2020 Feb; 69(2):207-217. PubMed ID: 31976856
[No Abstract] [Full Text] [Related]
19.
Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760135
[TBL] [Abstract][Full Text] [Related]
20. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.
Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B
Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547
[No Abstract] [Full Text] [Related]
[Next] [New Search]
